IMR Press / FBE / Volume 8 / Issue 1 / DOI: 10.2741/E763

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Treatment of brain metastases of lung cancer in the era of precision medicine

Show Less
1 Department of Medicine, Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA
2 Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA
3 W.G. (Bill) Hefner Veteran Administration Medical Center, Cancer Center, Salisbury, NC, USA
4 Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC, USA
5 Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA

*Author to whom correspondence should be addressed.

Academic Editor: Kounosuke Watabe

Front. Biosci. (Elite Ed) 2016, 8(1), 219–232; https://doi.org/10.2741/E763
Published: 1 January 2016
(This article belongs to the Special Issue Pathogenesis of tumor progression in breast and prostate cancer)
Abstract

Common and deadly complications of non-small cell lung cancer (NSCLC) are brain metastases (BM). BM portends a poorer prognosis with limited effective treatment options and current management strategies present several challenges from iatrogenic complications of supportive medications, optimal delivery of drug across the blood-brain barrier, and preservation of neurocognitive function. Long term side effects and survivorship issues have become more evident in the era of targeted therapy where a systemic disease is much better controlled. Targeted therapies and immunotherapy are beginning to provide improvements in responses and survival rates. With further advancements and experience, our knowledge in this era of precision medicine will likely lead to strides in improving the quality of life and overall survival of patients with BM from NSCLC. In this review, we present the most recent updates in treatment of BM in NSCLC in regards to targeted and immunotherapy.

Keywords
Brain Metastasis
Targeted Agents
Stereotactic Radiosurgery
Chemotherapy
Precision Medicine
Review
Share
Back to top